Literature DB >> 9028740

Inflammatory bowel disease management. Some thoughts on future drug developments.

J Rhodes1, G Thomas, B K Evans.   

Abstract

This article is intended to stimulate thought and focus on those areas where we feel advances in drug therapy for inflammatory bowel disease may occur. It is not an extensive review of current practice, although this is considered where it is thought to be pertinent to future developments. There are several excellent reviews of current practice which we do not attempt to repeat, nor do we give a comprehensive set of references, but cite well referenced reviews where necessary. New therapeutic developments should ideally stem from an understanding of the cause of pathogenesis of a condition; alternatively, established therapies may be modified or used as a basis for progress. Since the causes of both ulcerative colitis and Crohn's disease remain unknown, most forward thinking on drug development must come from current practice, but remain open to novel approaches. Our thoughts on possible future treatments for inflammatory bowel disease are somewhat selective, and because of their speculative nature are unlikely to coincide with those of others-only the future will reveal genuine advances as they become incorporated into established practice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9028740     DOI: 10.2165/00003495-199753020-00001

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  31 in total

1.  Release of drugs formulated as hard pastes filled into hard gelatin capsules. Part 1. Physical properties and in vitro testing.

Authors:  M Djimbo; A J Moës
Journal:  J Pharm Belg       Date:  1984 Jan-Feb

2.  Non-smoking: a feature of ulcerative colitis.

Authors:  A D Harries; A Baird; J Rhodes
Journal:  Br Med J (Clin Res Ed)       Date:  1982-03-06

3.  A pharmacokinetic study of sulphasalazine and two new formulations of mesalazine.

Authors:  G L Swift; C M Mills; J Rhodes; B K Evans; A Bennett; I A Tavares
Journal:  Aliment Pharmacol Ther       Date:  1992-04       Impact factor: 8.171

4.  5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.

Authors:  S N Rasmussen; S Bondesen; E F Hvidberg; S H Hansen; V Binder; S Halskov; H Flachs
Journal:  Gastroenterology       Date:  1982-11       Impact factor: 22.682

5.  Inflammatory bowel disorders: current and future drugs that modulate adhesion molecules.

Authors:  C J Bell; J L Wallace
Journal:  BioDrugs       Date:  1997-04       Impact factor: 5.807

6.  Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.

Authors:  C P Willoughby; J K Aronson; H Agback; N O Bodin; S C Truelove
Journal:  Gut       Date:  1982-12       Impact factor: 23.059

7.  Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide.

Authors:  R P Chan; D J Pope; A P Gilbert; P J Sacra; J H Baron; J E Lennard-Jones
Journal:  Dig Dis Sci       Date:  1983-07       Impact factor: 3.199

8.  A comparison of budesonide with prednisolone for active Crohn's disease.

Authors:  P Rutgeerts; R Löfberg; H Malchow; C Lamers; G Olaison; D Jewell; A Danielsson; H Goebell; O O Thomsen; H Lorenz-Meyer
Journal:  N Engl J Med       Date:  1994-09-29       Impact factor: 91.245

9.  An oral preparation to release drugs in the human colon.

Authors:  M J Dew; P J Hughes; M G Lee; B K Evans; J Rhodes
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

10.  Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial.

Authors:  R D Pullan; S Ganesh; V Mani; J Morris; B K Evans; G T Williams; J Rhodes
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

View more
  7 in total

1.  Current medical therapy for ulcerative colitis.

Authors:  Chang-Tai Xu; Bo-Rong Pan
Journal:  World J Gastroenterol       Date:  1999-02       Impact factor: 5.742

Review 2.  [Pharmacokinetic data for different 5-aminosalicylic acid and budesonide preparations].

Authors:  U Klotz
Journal:  Med Klin (Munich)       Date:  1999-02-15

3.  Effects of pentasa-combined probiotics on the microflora structure and prognosis of patients with inflammatory bowel disease.

Authors:  Hua Fan; Juan Du; Xia Liu; Wei-Wei Zheng; Ze-Hao Zhuang; Cheng-Dang Wang; Rui Gao
Journal:  Turk J Gastroenterol       Date:  2019-08       Impact factor: 1.852

Review 4.  Advances in colonic drug delivery.

Authors:  Abdul W Basit
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 5.  Cost of illness of Crohn's disease.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 6.  Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.

Authors:  A Prakash; A Markham
Journal:  Drugs       Date:  1999-03       Impact factor: 11.431

7.  The treatment of advanced renal cell cancer with high-dose oral thalidomide.

Authors:  J Stebbing; C Benson; T Eisen; L Pyle; K Smalley; H Bridle; I Mak; F Sapunar; R Ahern; M E Gore
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.